Orchestra BioMed Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on June 23, 2026. The record date for the meeting was April 28, 2026. A total of 59,880,715 shares were entitled to vote, with 49,053,298 shares represented at the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on five proposals, all of which were approved or acted upon as follows:
- Proposal 1 (Election of Directors): Three Class III director nominees were elected to serve until the 2029 annual meeting.
- David P. Hochman: 39,724,691 votes for.
- Darren R. Sherman: 39,544,240 votes for.
- Eric S. Fain: 37,810,358 votes for.
- Proposal 2 (Auditor Ratification): Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was approved with 49,039,578 votes for.
- Proposal 3 (Employee Stock Purchase Plan): The 2026 Employee Stock Purchase Plan was approved with 39,639,592 votes for.
- Proposal 4 (Say-on-Pay): The advisory vote on Named Executive Officer (NEO) compensation was approved with 37,975,986 votes for.
- Proposal 5 (Say-on-Pay Frequency): Stockholders voted to hold advisory compensation votes every 1 year (38,995,022 votes). The Company intends to submit this vote at every annual meeting until the next required frequency vote in 2032.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, specific risks, or contingencies. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the full text of the definitive proxy statement filed on April 29, 2026, for details on the director nominees and executive compensation.
- Confirm the implementation timeline for the newly approved 2026 Employee Stock Purchase Plan.
- Monitor future filings for the Company's 2026 annual financial results, as this 8-K contains no financial data.
- Note the commitment to annual "say-on-pay" votes through 2032.